BIRB 796 (Doramapimod) 化学構造
分子量: 527.66



Quality Control & MSDS


  • Compare p38 MAPK Inhibitors
    p38 MAPK製品生物活性の比較
  • 研究分野
  • BIRB 796 (Doramapimod)のメカニズム



製品説明 BIRB 796 (Doramapimod)はp38αMAPKの高さ選択阻害剤、THP-1細胞に作用する時、EC50が18nMになる。

p38α MAPK


0.1 nM (Kd) [1]

In vitro試験 BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwM{S3OlMh|ryP NF3kUpNUSU6JUlXS
DU-145 M1r5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPKTWM2OD1|LkmzPFEyKM7:TR?= M1zuN3NCVkeURWK=
GOTO M2fwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknZTWM2OD14LkO5NVYyKM7:TR?= M1m3d3NCVkeURWK=
NCI-H358 NGXCS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XEXmlEPTB;Nz61N|gh|ryP NGnKNnZUSU6JUlXS
IST-MES1 NIS5O|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwOUW2N|ch|ryP NG[0RXlUSU6JUlXS
KP-N-YN NGPER25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD16LkKwNVkh|ryP NHjuc5ZUSU6JUlXS
T-24 M2e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jOfWlEPTB;OD60NFY4OyEQvF2= M4Xl[XNCVkeURWK=
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRThwNE[yOVEh|ryP MlnZV2FPT1KHUh?=
MS-1 NUL6V2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGftcY5KSzVyPUGwMlgzOzVizszN NVrsXlRuW0GQR2LFVi=>
NBsusSR M4Lh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLYTWM2OD1zMD64NlM2KM7:TR?= NWfBZZlrW0GQR2LFVi=>
HMV-II MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXPTWM2OD1zND6yN|A6KM7:TR?= MnizV2FPT1KHUh?=
NCI-H1581 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHuTWM2OD1zNz6wOFQ4KM7:TR?= NGnRdJlUSU6JUlXS
ES8 NFjDbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF5LkG2O{DPxE1? NUHudWdbW0GQR2LFVi=>
LC-2-ad MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD1zNz60N|Y3KM7:TR?= MXjTRW5IWkWU
AN3-CA NHTwdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF6LkGg{txO Ml3JV2FPT1KHUh?=
DB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXezTHRGUUN3ME2xPE44QTJ|IN88US=> Ml\PV2FPT1KHUh?=
SK-MEL-1 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TzfmlEPTB;MkCuN|Y5OyEQvF2= NHG5bJhUSU6JUlXS
CAPAN-1 M3vQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqyfHdWUUN3ME2yNk4yQDh2IN88US=> NYfNSIhTW0GQR2LFVi=>
NCI-H2228 M1rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnpTWM2OD1{Mz62OlY5KM7:TR?= M3TpS3NCVkeURWK=
HOP-92 M1\HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTVTWM2OD1{ND6zPFM5KM7:TR?= M320eXNCVkeURWK=
KYSE-270 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiVlJ2UUN3ME2yOE42PTd|IN88US=> Mn;xV2FPT1KHUh?=
HCC1806 NWjqeIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vIdWlEPTB;MkSuO|c6QSEQvF2= M4C1e3NCVkeURWK=
HuO-3N1 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ3LkixPFUh|ryP MkXrV2FPT1KHUh?=
KYSE-510 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLWUpl1UUN3ME2yOk4yPjF{IN88US=> MnTzV2FPT1KHUh?=
COLO-741 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74fVlKSzVyPUK2MlM{OjlizszN MXLTRW5IWkWU
H-EMC-SS NYW2cnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPIdoZKSzVyPUK2MlkzPDVizszN M2m3O3NCVkeURWK=
HCC1937 NEjoNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3lTWM2OD1{Nz6yNlM5KM7:TR?= MUTTRW5IWkWU
NCI-H2126 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTsenl2UUN3ME2yO{4{QTd3IN88US=> MXvTRW5IWkWU
NCI-H1703 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XmT2lEPTB;MkiuNFQyOyEQvF2= NF;wO5lUSU6JUlXS
U-2-OS M2fpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDhO2VlUUN3ME2yPE42PTF3IN88US=> NV[wTYhpW0GQR2LFVi=>
DBTRG-05MG NF\NSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\FcmlEPTB;MkiuOVY2OSEQvF2= M3jiTnNCVkeURWK=
MHH-ES-1 M3:1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITRbmFKSzVyPUOxMlk1OSEQvF2= NIHyU4pUSU6JUlXS
HCC1419 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPKZm95UUN3ME2zNk4yOTF7IN88US=> MYnTRW5IWkWU
HOP-62 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLuTWM2OD1|Mj6yO|AyKM7:TR?= MmHQV2FPT1KHUh?=
AM-38 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTN{Lkm5N|Eh|ryP M3m4c3NCVkeURWK=
NCI-H2009 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInhOIhKSzVyPUOzMlQxODdizszN NYHlelV3W0GQR2LFVi=>
EM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN|LkW1NVEh|ryP NGP5NopUSU6JUlXS
SW1116 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P4WmlEPTB;M{SuOFg{QCEQvF2= NUPOTXJ1W0GQR2LFVi=>
SK-N-AS M2DvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jrfmlEPTB;M{WuNFcyPCEQvF2= MmrhV2FPT1KHUh?=
ChaGo-K-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDmPYRKSzVyPUO1MlYxOzJizszN NV3xWJlrW0GQR2LFVi=>
RT-112 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDMZY5KSzVyPUO1Mlk5PzlizszN M3zXd3NCVkeURWK=
LB831-BLC Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfwTWM2OD1|Nz62OVQyKM7:TR?= NYrFZlU1W0GQR2LFVi=>
CTB-1 NVvoe495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PyUmlEPTB;M{iuOFUyOiEQvF2= M1\QcXNCVkeURWK=
MOLT-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThUGlEPTB;M{iuPFM6OSEQvF2= NH\mW4dUSU6JUlXS
SW756 NIHzOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrsZpU3UUN3ME20NE46Ozh3IN88US=> NXzzWmtrW0GQR2LFVi=>
CAL-72 MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXNdHdKSzVyPUSyMlA{KM7:TR?= MlvjV2FPT1KHUh?=
KNS-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;TTWM2OD12Mj62Nlk3KM7:TR?= MVvTRW5IWkWU
HEL Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR3LkS2OFYh|ryP MoDNV2FPT1KHUh?=
KP-4 NFvoSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR4LkezOlEh|ryP MYjTRW5IWkWU
NEC8 M{XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hjc2lEPTB;NEeuNVY3OSEQvF2= NYfCV25lW0GQR2LFVi=>
G-402 NHSzUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;TTWM2OD12OD63NFEzKM7:TR?= NWfSS3pNW0GQR2LFVi=>

... Click to View More Cell Line Experimental Data

In vivo試験 BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. [2]
臨床試験 Boehringer Ingelheim has announced the discontinuation of BIRB 796 R&D project in 2005.
特集 The first p38 MAPK inhibitor to be tested in a phase III clinical trial.

プロトコル (参考用のみ)



Procedures for the THP-1 cellular assay for inhibition of LPS-stimulated TNF-α production THP-1 cells are preincubated in the presence and absence of BIRB 796 for 30 min. Cell mixture is stimulated with LPS (1 μg/mL final) and incubation continued overnight (18−24 hours) as above. Supernatant is analyzed for human TNF-α by a commercially available ELISA. Data are combined and analyzed by nonlinear regression using a three parameter logistic model to obtain an EC50 value. BIRB 796 is analyzed in each experiment and the 95% confidence intervals for the EC50 are between 16 and 22 nM.



動物モデル Collagen-induced arthritis in female Balb/c mice
製剤 70% PEG400 (intravenous) or 100% PEG400 (oral)
投薬量 1 mg/kg (intravenous) or 10 mg/kg (oral)
投与方法 Intravenous injection or by oral

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download BIRB 796 (Doramapimod) SDF
分子量 527.66


CAS No. 285983-48-4
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 106 mg/mL (200.88 mM)
エタノール 106 mg/mL (200.88 mM)
<1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea

カスタマーフィードバック (5)

Click to enlarge
Source Blood, 2012, 119(26), 6255-8. BIRB 796 (Doramapimod) purchased from Selleck
Method FACS analysis
Cell Lines B-lymphoid, myeloid cells
Concentrations 400 nM
Incubation Time
Results To further determine the content of functional HSPC in these cultures, it transplanted cells to sublethally irradiated Nod Scid Gamma (NSG) mice. Then, the engrafted cells showed robust repopulation of both the myeloid and lymphoid lineage, when cultured with BIRB796 (400 nM).

Click to enlarge
Source Cancer Lett, 2012, 324(1), 98-108. BIRB 796 (Doramapimod) purchased from Selleck
Method Western blot
Cell Lines HT-29 cells
Concentrations 0.1 uM
Incubation Time 24, 48, 72 h
Results Here it show that in CRC cells pharmacologic inhibition of p38α potentiates the MEK/ERK pathway, irrespectively of the mutational status of the ERK upstream activators RAS and RAF. Indeed, BIRB796 increased phospho-activation of ERK1/2 was observed in BRAF mutant HT-29 cells.

Click to enlarge
Source Int J Cancer, 2014, 134(3), 575-86. BIRB 796 (Doramapimod) purchased from Selleck
Method Western blot
Cell Lines Peripheral blood mononuclear cells
Concentrations 0.1 mM
Incubation Time 30 min
Results It confirmed that the inhibitors were blocking downstream p38 signaling by measuring MK2 phosphorylation in moDC. Treatment with SB203580 or BIRB0796 1.0 mM prevented TLR-induced MK2 phosphorylation, whereas 0.1 mM BIRB0796 did not fully inhibit MK2 activation. BIRB0796 did not affect phospho-p38 activation but ablated ERK phosphorylation.

Click to enlarge
Source Biochem J, 2014, 449(2), 497-506. BIRB 796 (Doramapimod) purchased from Selleck
Method Western blot
Cell Lines NIH 3T3 cells
Concentrations 50 nM
Incubation Time 2 h
Results Therefore it tested BIRB796, an inhibitor structurally unrelated to SB203580 that blocks the ATP-binding site of p38 MAPK. NIH 3T3 cells were pretreated with BIRB796 and then incubated under starvation conditions with or without 10 mM glucose for 2 h. Lipidation of LC3 was analysed by Western blotting. As shown in Figure, BIRB796 repressed the accumulation of LC3-II induced by glucose.

Click to enlarge
Source BIRB 796 (Doramapimod) purchased from Selleck
Method Western blot
Cell Lines HEK293 cells
Concentrations 0.01-1 μM
Incubation Time 1 h
Results BIRB796 treatment resulted in a reduction of p38 phosphorylation in HEK293 cells.

文献中の引用 (17)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related p38 MAPK 阻害剤

  • Pexmetinib (ARRY-614)

    Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

  • SB239063

    SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • SB203580


    Features:First reported p38 inhibitor.

  • SB202190 (FHPI)

    SB202190 (FHPI)は、p38α</b、p38βを目標としている強力なp38 MAPK阻害剤で、IC50 がそれぞれ 50 nM と 100 nMです。

  • LY2228820

    LY2228820は、p38 MAPKの新しくて強力な阻害剤で、 IC50 が7 nMになる。

  • Losmapimod (GW856553X)

    Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.

  • PH-797804



Tags: BIRB 796 (Doramapimod)を買う | BIRB 796 (Doramapimod)供給者 | BIRB 796 (Doramapimod)を購入する | BIRB 796 (Doramapimod)費用 | BIRB 796 (Doramapimod)生産者 | オーダーBIRB 796 (Doramapimod) | BIRB 796 (Doramapimod)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID